Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option

Sari M.

Journal of Cancer Research and Therapeutics, vol.16, no.4, pp.900-902, 2020 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 4
  • Publication Date: 2020
  • Doi Number: 10.4103/jcrt.jcrt_169_19
  • Journal Name: Journal of Cancer Research and Therapeutics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.900-902
  • Keywords: Aggressive fibromatosis, meloxicam, oral tyrosine kinase inhibitor, sorafenib
  • Marmara University Affiliated: No

Abstract

Objective: Aggressive fibromatosis (AF), also called desmoid tumor, is an uncommon soft-tissue neoplasm. Characteristically, it expands locally without metastatic potential. However, its tendency of relapse after curative resections has been well documented. Effective treatment options have been limited and there is a clear need for novel treatment strategies. Methods: We used combination therapy including multikinase tyrosine kinase inhibitor for treating AF. Results: We presented a case of an extra-abdominal AF who was successfully treated with meloxicam and sorafenib combination in our clinic. She tolerated this therapy well with only mild side effects. To our knowledge, this is the first case report of an extra-abdominal AF with a major partial response to sorafenib and meloxicam combination. Conclusion: Due to the favorable toxicity profile of sorafenib and meloxicam, this combination might be an effective treatment option for patients with locally aggressive and inoperable AF.